| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pertuzumab |
| Brand | Perjeta® |
| Indication | Is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 01/06/2018 |
| Rapid review completed | 22/06/2018 |
| Rapid review outcome | A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 22/06/2018 |
| Pre-submission consultation with Applicant | 31/07/2018 |
| Full submission received from Applicant | 14/09/2018 |
| Preliminary review sent to Applicant | 13/11/2018 |
| Follow-up to preliminary review sent to Applicant | 27/11/2018 |
| NCPE assessment re-commenced | 03/12/2018 |
| Factual accuracy sent to Applicant | 11/01/2019 |
| NCPE assessment re-commenced | 18/01/2019 |
| NCPE assessment completed | 31/01/2019 |
| NCPE assessment outcome | The NCPE recommends that pertuzumab (in combination with trastuzumab and chemotherapy) for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease), not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
